Using Optical Coherence Tomography and Noninvasive Retinal Amyloid Imaging to Capture Retinal Changes Associated With Dementia

Oregon Health and Science University1 site in 1 country20 target enrollmentSeptember 14, 2018

ConditionsAlzheimer Disease Dementia Mild Cognitive Impairment

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Alzheimer Disease
Sponsor: Oregon Health and Science University
Enrollment: 20
Locations: 1
Primary Endpoint: Retinal amyloid protein detection
Status: Recruiting
Last Updated: 7 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to:

Detect retinal blood vessel and blood flow changes in participants with dementia.
Detect amyloid protein deposits in the retinas of participants with dementia.

Registry

clinicaltrials.gov

Start Date

September 14, 2018

End Date

December 1, 2027

Last Updated

7 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Oregon Health and Science University

Responsible Party

Principal Investigator

David Huang

David Huang, MD, PhD, Peterson Professor of Ophthalmology and Professor orf Biomedical Engineering

Oregon Health and Science University

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Retinal amyloid protein detection

Time Frame: 1 day

OCT and OCT angiography will be used to detect levels of amyloid proteins deposits within the retina layers on the single enrollment visit only. An increase in the protein detection is expected in the dementia group.